IRIS Accounts Production v24.3.0.553 11240370 director 1.4.23 31.3.24 31.3.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh112403702023-03-31112403702024-03-31112403702023-04-012024-03-31112403702022-03-31112403702022-04-012023-03-31112403702023-03-3111240370ns15:EnglandWales2023-04-012024-03-3111240370ns14:PoundSterling2023-04-012024-03-3111240370ns10:Director12023-04-012024-03-3111240370ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3111240370ns10:SmallEntities2023-04-012024-03-3111240370ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3111240370ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3111240370ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3111240370ns10:FullAccounts2023-04-012024-03-3111240370ns5:CurrentFinancialInstruments2024-03-3111240370ns5:CurrentFinancialInstruments2023-03-3111240370ns5:ShareCapital2024-03-3111240370ns5:ShareCapital2023-03-3111240370ns5:RetainedEarningsAccumulatedLosses2024-03-3111240370ns5:RetainedEarningsAccumulatedLosses2023-03-3111240370ns10:RegisteredOffice2023-04-012024-03-3111240370ns5:FurnitureFittings2023-04-012024-03-3111240370ns5:ComputerEquipment2023-04-012024-03-3111240370ns5:FurnitureFittings2023-03-3111240370ns5:ComputerEquipment2023-03-3111240370ns5:FurnitureFittings2024-03-3111240370ns5:ComputerEquipment2024-03-3111240370ns5:FurnitureFittings2023-03-3111240370ns5:ComputerEquipment2023-03-3111240370ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3111240370ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-31
REGISTERED NUMBER: 11240370 (England and Wales)









Unaudited Financial Statements

for the Year Ended 31 March 2024

for

Medrus Pharma Consulting Limited

Medrus Pharma Consulting Limited (Registered number: 11240370)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Balance Sheet 1

Notes to the Financial Statements 2


Medrus Pharma Consulting Limited (Registered number: 11240370)

Balance Sheet
31 March 2024

31.3.24 31.3.23
Notes £    £   
FIXED ASSETS
Tangible assets 4 503 593

CURRENT ASSETS
Debtors 5 110 110
Cash at bank 51,220 50,090
51,330 50,200
CREDITORS
Amounts falling due within one year 6 (4,528 ) (4,229 )
NET CURRENT ASSETS 46,802 45,971
TOTAL ASSETS LESS CURRENT LIABILITIES 47,305 46,564

CAPITAL AND RESERVES
Called up share capital 110 110
Retained earnings 47,195 46,454
47,305 46,564

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 4 October 2024 and were signed by:





Dr A J Jones - Director


Medrus Pharma Consulting Limited (Registered number: 11240370)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

Medrus Pharma Consulting Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 11240370

Registered office: Westminster House
10 Westminster Road
Macclesfield
Cheshire
SK10 1BX

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable.

When the outcome of a transaction can be estimated reliably, turnover from services is recognised by reference to the stage of completion at the balance sheet date. Stage of completion is measured by reference to finalisation of work completed.

Where the outcome cannot be measured reliably, turnover is recognised only to the extent of the expenses recognised that are recoverable.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 15% on reducing balance
Computer equipment - 33% on cost

Taxation
Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

Medrus Pharma Consulting Limited (Registered number: 11240370)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

4. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 April 2023 115 987 1,102
Additions 115 - 115
At 31 March 2024 230 987 1,217
DEPRECIATION
At 1 April 2023 59 450 509
Charge for year 26 179 205
At 31 March 2024 85 629 714
NET BOOK VALUE
At 31 March 2024 145 358 503
At 31 March 2023 56 537 593

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Other debtors 110 110

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade creditors 65 65
Taxation and social security 3,228 2,427
Other creditors 1,235 1,737
4,528 4,229